Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Holmgren

Showing results (31-40 of 126) with videos related to

Pageof 13
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|April 3, 2003
Recent developments in mucosal immunomodulatory adjuvantsAli M Harandi, Joaquin Sanchez, Kristina Eriksson, et al.
Journal of Reproductive Immunology|October 19, 2005
CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in miceSara Tengvall, Agnetha Josefsson, Jan Holmgren, et al.
Applied Microbiology and Biotechnology|April 21, 2010
Construction and expression of immunogenic hybrid enterotoxigenic Escherichia coli CFA/I and CS2 colonization fimbriae for use in vaccinesJoshua Tobias, Ann-Mari Svennerholm, Jan Holmgren, et al.
The Journal of General Virology|March 21, 2001
Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in miceAli M Harandi, Bo Svennerholm, Jan Holmgren, et al.
Expert Review of Vaccines|June 5, 2004
Current status and future prospects for a vaccine against schistosomiasisMichael Lebens, Jia-Bin Sun, Cecil Czerkinsky, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 20, 2015
Cholera toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP-protein kinase A and inflammasome-dependent IL-1 signalingMaximilian Larena, Jan Holmgren, Michael Lebens, et al.
The Journal of Biological Chemistry|June 29, 2002
Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (STa-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccinationJoaquín Sánchez, Gun Wallerström, Margareta Fredriksson, et al.
Journal of Immunological Methods|July 9, 2008
Phage display for site-specific immunization and characterization of high-risk human papillomavirus specific E7 monoclonal antibodiesMaria Lidqvist, Olle Nilsson, Jan Holmgren, et al.
Vaccine|April 23, 2026
Improving cholera vaccination impact through advances in gut mucosal immunology: outcomes of a 2025 expert consultationAnna Lundgren, Kirsten Vannice, Edward Ryan, et al.
Nature Immunology|November 17, 2010
Ten years of the Global Alliance for Vaccines and Immunization: challenges and progressJohn Clemens, Jan Holmgren, Stefan H E Kaufmann, et al.
Pageof 13

Showing results (31-40 of 126) with videos related to

Sort By:
Pageof 13
Current Opinion in Investigational Drugs (London, England : 2000)|April 3, 2003
Recent developments in mucosal immunomodulatory adjuvantsAli M Harandi, Joaquin Sanchez, Kristina Eriksson, et al.
Journal of Reproductive Immunology|October 19, 2005
CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in miceSara Tengvall, Agnetha Josefsson, Jan Holmgren, et al.
Applied Microbiology and Biotechnology|April 21, 2010
Construction and expression of immunogenic hybrid enterotoxigenic Escherichia coli CFA/I and CS2 colonization fimbriae for use in vaccinesJoshua Tobias, Ann-Mari Svennerholm, Jan Holmgren, et al.
The Journal of General Virology|March 21, 2001
Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in miceAli M Harandi, Bo Svennerholm, Jan Holmgren, et al.
Expert Review of Vaccines|June 5, 2004
Current status and future prospects for a vaccine against schistosomiasisMichael Lebens, Jia-Bin Sun, Cecil Czerkinsky, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 20, 2015
Cholera toxin, and the related nontoxic adjuvants mmCT and dmLT, promote human Th17 responses via cyclic AMP-protein kinase A and inflammasome-dependent IL-1 signalingMaximilian Larena, Jan Holmgren, Michael Lebens, et al.
The Journal of Biological Chemistry|June 29, 2002
Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (STa-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccinationJoaquín Sánchez, Gun Wallerström, Margareta Fredriksson, et al.
Journal of Immunological Methods|July 9, 2008
Phage display for site-specific immunization and characterization of high-risk human papillomavirus specific E7 monoclonal antibodiesMaria Lidqvist, Olle Nilsson, Jan Holmgren, et al.
Vaccine|April 23, 2026
Improving cholera vaccination impact through advances in gut mucosal immunology: outcomes of a 2025 expert consultationAnna Lundgren, Kirsten Vannice, Edward Ryan, et al.
Nature Immunology|November 17, 2010
Ten years of the Global Alliance for Vaccines and Immunization: challenges and progressJohn Clemens, Jan Holmgren, Stefan H E Kaufmann, et al.
Pageof 13